Large genetic study reveals causes for insulin resistance, metabolic syndrome

A team of researchers use a unique ratio to uncover the causes of these mysterious conditions

12:02 PM

Author | Jina Sawani

Image of woman with scientific objects, focusing on insulin resistance
Getty Images

Insulin resistance has long been identified as the cause of diabetes, but many are unaware that it can also predispose some forms of cancer and other metabolic conditions, like obesity, dyslipidemia, hypertension, cardiovascular disease and metabolic dysfunction-associated steatotic liver disease, or MASLD.

However, due to a relatively poor understanding of its causes, there are currently very few treatments for insulin resistance. 

Insulin resistance remains “hard to study” from a research perspective, said Elizabeth Speliotes, M.D., Ph.D., M.P.H., who serves as a gastroenterologist at Michigan Medicine and professor of internal medicine and computational medicine and bioinformatics at the University of Michigan Medical School. She is a member of the Elizabeth Weiser Caswell Diabetes Institute.

“Studying this condition requires cumbersome and oftentimes expensive gold standard measures,” she said. “The condition is genetically influenced, but only a limited number of genes affecting this trait have been identified at this point in time.” 

Studying genetic components

This gap in understanding of the pathophysiology of this central cause of many metabolic diseases inspired Speliotes and a team of fellow researchers to further study its genetic components. Their findings were recently published in Nature Genetics

“In our study, we used a more easily measured proxy of insulin resistance, the serum triglycerides to high-density lipoprotein cholesterol, or TG:HDL-C, ratio,” said Antonino Oliveri, first author of the study and an analyst in Speliotes’ laboratory. 

“Serum triglycerides and high-density lipoprotein cholesterol can be conveniently quantified with a blood test. Essentially, this helped us carry out a much larger study of an insulin resistance marker, surpassing the scale of previous genetic studies of similar markers.” 

The team’s study involved 402,398 Europeans from the U.K. Biobank, an extensive biomedical database and research resource containing de-identified genetic and health data and biological samples. 

In addition, they identified over 350 loci, or points, within the human genome that are associated with the insulin resistance measure TG:HDL-C. 

“Given the practicability of the trait we used, our work involved a marked increase in loci in comparison to previous studies of insulin resistance markers, becoming the largest study of an insulin resistance marker and the only study about this trait to date,” said Oliveri. 

“Of the over 350 loci, 114 were also associated with the less powered serum insulin levels, HOMA-IR, which stands for Homeostatic Model Assessment for Insulin Resistance, or the Insulin Sensitivity Index, affirming specificity to insulin resistance.” 

Insulin resistance

The team also found that associated genetic variants identified adipose tissue, as well as various physiological systems, that were affected by insulin resistance. 

“Cardiovascular, liver, musculoskeletal and female urogenital systems were enriched for expression of genes implicated by the associated insulin resistance variants,” said Ryan Rebernick, who is an M.D. and Ph.D. candidate at U-M and co-first author of the study. 

“The implicated genes also highlighted insulin signaling and growth, metabolism and abnormal lipid homeostasis pathways. Specific insulin signaling and growth-related genes, including EP300, CREBBP, SMAD1, SMAD3, ESR1 and IGF1R. Therefore, these hold the potential to serve as new targets for understanding the disease.”

Rebernick added that “another highlighted pathway was related to serine and threonine signaling. And a third network that was identified was related to adipose biology.” 

“A decreased amount of white adipose tissue and altered functionality can cause lipodystrophy and promote insulin resistance,” he said. 

The researchers later went on to identify five new subtypes of disease based on the effects of the genetic variants with related metabolic traits. 

“These subtypes included brain processes, insulin and insulin growth, carbohydrate metabolism, adipogenesis and lipid homeostasis,” said Oliveri.

“We found that most, if not all, genomic variants that cause metabolic syndrome overlapped with the triglycerides to HDL-C ratio genomic variants. Metabolic syndrome, a condition that includes obesity, diabetes, and lipid and blood pressure defects can also lead to liver and cardiovascular diseases.” 

New insights

Speliotes, senior author of the study, noted that the causes of metabolic syndrome are still unknown, but added the team’s findings suggest a very strong link between the high triglycerides to HDL-C ratio, insulin resistance and metabolic syndrome.  

“Before this study, we had extremely limited insights into what causes insulin resistance, as well as metabolic syndrome,” said Speliotes. 

“But now, through this work, we have a much more robust understanding of the pathophysiology of these diseases. Ultimately, this will allow us to better identify and treat the causes of these conditions with greater efficacy and fewer side effects to alter the course of these common metabolic diseases, which is very exciting.” 

Additional authors: Annapurna Kuppa, Asmita Pant, Yanhua Chen, Xiaomeng Du, Kelly C. Cushing, Hannah N Bell, Chinmay Raut, Ponnandy Prabhu, Vincent L. Chen and Brian D. Halligan.

Paper cited: “Comprehensive genetic study of the insulin resistance marker TG:HDL-C in the UK Biobank,” Nature GeneticsDOI: 10.1038/s41588-023-01625-2

Sign up for the Health Lab Podcast: Add us on SpotifyApple Podcasts or wherever you get you listen to your favorite shows.


More Articles About:

Nonalcoholic fatty liver disease (NAFLD) Digestive (GI) Conditions Liver Conditions & Procedures Metabolism, Endocrinology & Diabetes
Health Lab word mark overlaying blue cells

Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

liver in bright green against navy background
Health Lab

Genetic variation with MASLD reveals subtypes and potential therapeutic avenues

A Michigan Medicine team of experts seeks to identify the human genetic causes of MASLD, formerly called NAFLD
A hand holding a scoop of protein powder hovering over a cup of water
Health Lab

Supplementing with peptides: Good for extra pep or a needless step?

Health Lab talks to Jorge Ruas, Ph.D., of the U-M Department of Pharmacology, about peptides, how they work and whether supplementing them lends any benefit.
donut with brain character looking at plate
Health Lab

New study reveals a missing step in a weight control pathway that could be targeted for obesity treatment

New research led by Liangyou Rui, Ph.D., of the Department of Molecular & Integrative Physiology at the University of Michigan Medical School outlines a missing step in one of these alternative pathways, an important discovery in the fight against obesity.
particles forming colorful in intestines
Health Lab

IBS treatment response predicted by gut microbiome in new study

A Michigan Medicine study finds the low FODMAP diet and the antibiotic rifaximin provided similar and significant relief for patients with irritable bowel syndrome with diarrhea (IBS-D).
little girl in hospital bed with liver pillow
Health Lab

2-year-old thrives after liver transplant for biliary atresia

Living donor allows 2-year-old to thrive after a liver transplant she needed.
risk of T1D development progessor non-progressor time
Health Lab

New hope for early diabetes detection

The research offers an actionable monitoring method that may guide the administration of current and emerging therapeutics more effectively than the current diagnostics that only assess disease risk or detect disease after destruction of insulin producing cells.